Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Apr;3(2):100-6.
doi: 10.4161/derm.3.2.14831. Epub 2011 Apr 1.

Pathogenesis of the Cutaneous Phenotype in Inherited Disorders of Cholesterol Metabolism: Therapeutic Implications for Topical Treatment of These Disorders

Affiliations
Free PMC article

Pathogenesis of the Cutaneous Phenotype in Inherited Disorders of Cholesterol Metabolism: Therapeutic Implications for Topical Treatment of These Disorders

Peter M Elias et al. Dermatoendocrinol. .
Free PMC article

Abstract

Molecular geneticists tend to conceptualize disease pathogenesis from the mutated gene outward, an approach that does not take into account the impact of barrier requirements in determining disease phenotype. An 'outside-to-inside' perspective has provided quite different explanations for the ichthyoses, including several of the disorders of distal cholesterol metabolism. Elucidation of responsible pathogenic mechanisms also is pointing to appropriate, pathogenesis (pathway)-based therapeutic strategies. In the case of the lipid metabolic disorders, it takes full advantage of new molecular, genetic and cellular pathogenesis information to correct or bypass the metabolic abnormality. This approach fully exploits the unique accessibility of the skin to a topical approach. Moreover, since it will utilize topical lipids and lipid-soluble, and often generic, lipid-soluble drugs, these treatments should be readily transported across the stratum corneum. If successful, this approach could initiate an entirely new departure for the therapy of the ichthyoses. Finally, because these agents are relatively safe and inexpensive, this form of treatment has the potential to be widely-deployed, even in the developing world.

Keywords: CDPX2; CHH syndrome; CHILD syndrome; SC4MOL; SC5D; SLOS; barrier function; cholesterol; desmosterolosis; ichthyosis; statin.

Figures

Figure 1
Figure 1
Enzymatic stages in distal cholesterol metabolites and their associated clinical disorders. Syndromic disorders occur with mutations in 7 of the 9 post-lanosterol steps in late cholesterol synthesis (indicated by bold/italics). A prominent cutaneous phenotype (ichthyosis) occurs in 6 of these diseases (indicated by bold/italics & underline).
Figure 2
Figure 2
Pathogenesis-based therapy for disorders of distal cholesterol metabolites: Bases for improvement in clinical studies.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

References

    1. Moskowitz DG, Fowler AJ, Heyman MB, Cohen SP, Crumrine D, Elias PM, et al. Pathophysiologic basis for growth failure in children with ichthyosis: an evaluation of cutaneous ultrastructure, epidermal permeability barrier function and energy expenditure. J Pediatr. 2004;145:82–92. - PubMed
    1. Elias PM, Williams ML, Holleran WM, Jiang YJ, Schmuth M. Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res. 2008;49:697–714. - PMC - PubMed
    1. Schmuth M, Gruber R, PM E, Williams M. Ichthyosis update: towards a function-driven model of pathogenesis of the disorders of cornification and the role of corneocyte proteins in these disorders. Adv Dermatol. 2007;23:231–256. - PMC - PubMed
    1. Elias PM, Feingold KR. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol. 2001;137:1079–1081. - PubMed
    1. Elias PM, Cullander C, Mauro T, Rassner U, Komuves L, Brown BE, et al. The secretory granular cell: the outermost granular cell as a specialized secretory cell. J Invest Dermatol Symp Proc. 1998;3:87–100. - PubMed

LinkOut - more resources

Feedback